Revolutionising Vaccine Development with Mucosal Immunity
More effective vaccines to protect against mucosal pathogens.
About Us
We’re developing an innovative vaccine platform that targets mucosal surfaces, such as the respiratory and gastrointestinal tracts — the body’s entry point for many pathogens.
Our adaptable “plug and display” technology is designed to accelerate vaccine development and enhance effectiveness against pathogens where traditional vaccines struggle to prevent.
MucVac is a biotech start-up founded by PhD researchers from the University of Manchester and our goal is to develop a proof-of-concept that proves the effectiveness of our platform.
The Global Challenge of Vaccine Gaps
Millions of people worldwide die each year from infectious diseases, yet many of these diseases either have no vaccine or existing vaccines are ineffective. One of the key reasons for this is that many pathogens enter the body through mucosal surfaces, but existing vaccines focus on systemic immunity, not mucosal immunity.
Limited Mucosal Protection
Vaccines struggle to target entry points
Most current vaccines don’t protect mucosal surfaces, where many infections begin, leaving gaps in disease prevention.
Rapidly Mutating Pathogens
Vaccines can’t keep up with mutations
Diseases like STIs and parasites mutate quickly, making traditional vaccines less effective against evolving pathogens.
High Global Mortality
Infectious diseases claim millions of lives
The lack of vaccines for fast-mutating and hard-to-target diseases contributes significantly to global mortality rates.
Our Solution
MucVac addresses these challenges with a “plug and display” vaccine platform specifically designed to elicit strong immune responses at mucosal surfaces.
Increased Effectiveness
Targeting mucosal surfaces enhances vaccine efficacy where systemic vaccines fall short, providing better protection against diseases like sexually transmitted infections and gastrointestinal pathogens.
Cost-Effective Production
By reducing the dosage required for protective immunity, our vaccines lower both production and administration costs.
Faster Vaccine Development
Our platform allows pharmaceutical companies to rapidly adapt immune targets and create new vaccine candidates, accelerating time-to-market.
